Amenamevir

Description: Amenamevir (formerly known as ASP2151) is a HSV (herpes simplex virus) helicase-primase inhibitor with potent antiviral activity against HSVs with EC50 of 14 ng/mL. Amenamevir a novel class of antiviral agent other than nucleoside compounds, such as aciclovir, valaciclovir and famciclovir.  Amenamevir 400 and 200 mg were well tolerated as well as valaciclovir. The proportions of patients who experienced drug-related adverse events were 10.0% (25/249), 10.7% (27/252) and 12.0% (30/249) with amenamevir 400 and 200 mg and valaciclovir, respectively. In conclusion, amenamevir 400 mg appears to be effective and well tolerated for treatment of herpes zoster in immunocompetent Japanese patients.